Latest Otc Medicines News

Xenitra Limited has secured A$1.5 million through a discounted share placement to accelerate growth in higher-margin OTC medicines, FSMP, and tokenised FMCG sales. The capital will fund inventory expansion, supplier fulfilment, and ecommerce activation as the company shifts from low-margin distribution to a diversified healthcare platform.

Xenitra’s Hong Kong subsidiary Fukang has inked a three-year A$5 million procurement framework for specialised medical nutrition products, broadening its foothold beyond OTC medicines in China’s booming healthcare market.

Xenitra Limited (ASX:XEN) has turned around its cash flow in Q4 FY26, reporting positive operating cash flow of A$0.8 million driven by a leaner cost base and a shift towards higher-margin OTC medicines and blockchain-enabled OPAL tokenised sales.

Xenitra has secured a three-year procurement agreement worth at least A$12 million with Kangsheng, a leading Chinese pharmaceutical distributor, marking its OTC pharmaceuticals division's shift from setup to commercial execution.

Xenitra Limited's OPAL Real World Asset tokenised sales ecosystem has generated over $500,000 in sales within its first month, onboarding more than 130 distributors and positioning the company as an early mover in blockchain-enabled FMCG sales in China.

Xenitra Limited has secured $1.25 million through a share placement to accelerate its OTC medicines rollout and expand its OPAL RWA token ecosystem, with shareholder approval pending for attached options.

Xenitra Limited has swiftly moved from concept to commercial traction, generating over $100,000 in sales within the first week of launching EZZ Life Sciences products on its blockchain-based OPAL token ecosystem.

Xenitra Limited’s Q3 sales soared to $8.3 million, a 300% jump over Q2, driven by its Nutritionals division and a strategic $30 million partnership with Rockcheck Group for Danone products. The company also launched new OTC medicines and blockchain tokenised sales channels poised to fuel future growth.

Xenitra Limited has acquired Hong Kong Fukang Trading Co., including key pharmaceutical licenses and ecommerce assets, to fully operationalise its OTC medicine business in Hong Kong and China.

Xenitra Limited (ASX:XEN) has introduced the OPAL Token and Xen Shop, a blockchain-based digital commerce ecosystem aimed at improving product authentication, customer loyalty, and sales transparency across its Asian FMCG markets.

Aumake Limited reported a sharp 45% drop in half-year revenue alongside a 24% increase in net loss, while securing new capital and a major distribution deal to support its pivot in the China market.

AuMake Limited reports positive operating cashflow and a strategic pivot into China’s high-growth OTC medicine market, supported by a $1.5 million capital raise and significant governance reforms.